Share on StockTwits

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) have earned an average rating of “Hold” from the seventeen ratings firms that are presently covering the stock, Analyst Ratings Network.com reports. Eight equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $102.82.

A number of research firms have recently commented on VRTX. Analysts at Zacks reiterated a “neutral” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, July 31st. They now have a $97.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 9th. Finally, analysts at Oppenheimer downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th.

Vertex Pharmaceuticals (NASDAQ:VRTX) opened at 91.76 on Tuesday. Vertex Pharmaceuticals has a 52 week low of $58.06 and a 52 week high of $99.74. The stock’s 50-day moving average is $92.5 and its 200-day moving average is $79.01. The company’s market cap is $21.846 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings data on Tuesday, July 29th. The company reported ($0.61) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.71) by $0.10. The company had revenue of $138.42 million for the quarter, compared to the consensus estimate of $131.85 million. During the same quarter in the prior year, the company posted ($0.03) earnings per share. The company’s quarterly revenue was down 55.5% on a year-over-year basis. Analysts expect that Vertex Pharmaceuticals will post $-2.90 EPS for the current fiscal year.

In other Vertex Pharmaceuticals news, Director Joshua S. Boger unloaded 5,200 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $91.51, for a total transaction of $475,852.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.